Moderate revenue decrease Pfizer expected

Moderate decrease Pfizer expected

Over the past book year the analyst estimate the revenue to be around 48,34 billion dollars. This is marginally more than the 2014's revenue of 49,41 billion dollars. The consensus of the analysts for 2015 is a net profit of 13,68 billion dollars.

For 2015 the consensus of the earnings per share of Pfizer is at profit of 2,18 dollars. Based on this the price/earnings-ratio equals 13,86.

The consensus of the dividends per share is at 1,06 dollars.Consequently the dividend return is around 3,51 percent. On average the stocks in this sector yield a dividend return of around 0,48 percent.

The stock Pfizer is covered by 12 analysts. The average target price for Pfizer is at 39,47 dollars. This is 22 percent more than the current stock price of 30,21 dollars.

The stocks Mithra, Kiadis and Shire in the sector pharmaceutical sector have the most buy recommendations. The 3 most recent recommendations for the pharmaceutical sector were provided by Barclays (hold, 34,00 dollars), Jefferies & Co. (buy, 47,00 dollars) and Independent Research (hold, 36,00 dollars).

Pfizer's book value/price equals 0,37. The pharmaceutical company now trades at a Shiller PE of 18.86. The stock now trades at 30,21 dollars. This equals 21 times the 2014's earnings per share. Nieuwsdienst: +31 084-0032-842

Copyright B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.